Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155
Debt
Debt-to-Equity RatioN/A
Current Ratio8.76
Quick Ratio8.76
Price-To-Earnings
Trailing P/E Ratio-1.43
Forward P/E Ratio-1.51
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.16 per share
Price / Book1.31
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-21,120,000.00
Net MarginsN/A
Return on Equity-83.89%
Return on Assets-77.84%
Miscellaneous
Employees14
Outstanding Shares8,340,000
Market Cap$34.95
Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions
What is Tonix Pharmaceuticals' stock symbol?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
How were Tonix Pharmaceuticals' earnings last quarter?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) posted its earnings results on Wednesday, May, 16th. The company reported ($0.88) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.18. View Tonix Pharmaceuticals' Earnings History.
When is Tonix Pharmaceuticals' next earnings date?
What price target have analysts set for TNXP?
7 Wall Street analysts have issued twelve-month target prices for Tonix Pharmaceuticals' stock. Their forecasts range from $6.00 to $9.00. On average, they expect Tonix Pharmaceuticals' share price to reach $7.6667 in the next year. This suggests a possible upside of 84.7% from the stock's current price. View Analyst Ratings for Tonix Pharmaceuticals.
What is the consensus analysts' recommendation for Tonix Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Tonix Pharmaceuticals' key competitors?
Some companies that are related to Tonix Pharmaceuticals include Nabriva Therapeutics (NBRV), Molecular Templates (MTEM), CytoDyn (CYDY), CTI BioPharma (CTIC), Catalyst Biosciences (CBIO), Conatus Pharmaceuticals (CNAT), Sol Gel Technologies (SLGL), Forward Pharma A/S (FWP), Juniper Pharmaceuticals (JNP), MOTIF BIO PLC/S (MTFB), Leap Therapeutics (LPTX), Adamis Pharmaceuticals (ADMP), Steadymed (STDY), Recro Pharma (REPH) and Iterum Therapeutics (ITRM).
Who are Tonix Pharmaceuticals' key executives?
Tonix Pharmaceuticals' management team includes the folowing people:
- Dr. Seth Lederman M.D., Co-Founder, Pres, CEO & Chairman (Age 60)
- Dr. Donald W. Landry, Co-Founder & Director (Age 63)
- Mr. Bradley Saenger CPA, CFO & Treasurer (Age 44)
- Dr. Gregory M. Sullivan M.D., Chief Medical Officer & Sec. (Age 52)
- Mrs. Jessica Edgar Morris, Chief Operating Officer
Has Tonix Pharmaceuticals been receiving favorable news coverage?
Media stories about TNXP stock have trended somewhat positive on Saturday, according to Accern. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the company an impact score of 46.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Tonix Pharmaceuticals?
Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tonix Pharmaceuticals' stock price today?
One share of TNXP stock can currently be purchased for approximately $4.15.
How big of a company is Tonix Pharmaceuticals?
Tonix Pharmaceuticals has a market capitalization of $34.95 million. The company earns $-21,120,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Tonix Pharmaceuticals employs 14 workers across the globe.
How can I contact Tonix Pharmaceuticals?
Tonix Pharmaceuticals' mailing address is 509 MADISON AVE. - SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]
MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
